Factors Driving Use of Adjuvant Therapy for Stage III Melanoma
Source: Cancer Therapy Advisor, April 2024
A survey of oncologists and review of patient data revealed factors driving decisions about adjuvant therapy for patients with stage III melanoma.
The study showed that disease substage, insurance status, and ECOG performance status are all significantly associated with the likelihood of receiving adjuvant therapy. The researchers reported these and other findings in BMC Cancer.
The study consisted of a survey sent to 152 US medical oncologists who reviewed the charts of 507 patients with stage III melanoma.